Skip to main content

Table 2 Characteristics of epirubicin-treated patients by UGT2B7His268Tyrgenotype

From: Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

UGT2B7268 Genotype Tyr/Tyr His/Tyr + His/His P
Number (%) 66 (32.2%) 139 (67.8%)  
Age in years (mean, SD) 50.1 (10.7) 54.4 (10.2) 0.01
Tumor size    0.12
   ≤ T1 (≤ 20 mm) 29 (43.9%) 46 (33.1%)  
   ≥ T2 35 (53.0%) 92 (66.2%)  
   unknown 2 (3.0%) 1 (0.7%)  
Lymph nodes    0.73
   0 12 (18.2%) 20 (14.4%)  
   ≥ 1 50 (75.8%) 112 (80.6%)  
   unknown 4 (6.1%) 7 (5.0%)  
Grade    0.62
   1 1 (1.5%) 2 (1.4%)  
   2 17 (25.8%) 46 (33.1%)  
   > 2 43 (65.2%) 85 (61.2%)  
   Unknown 5 (7.6%) 6 (4.3%)  
  1. SD, standard deviation